Sanofi and Bayer are swapping out two top execs, triggering a reorganization at the French pharma company that will allow for a closer focus on China.
Stefan Oelrich is leaving his job at Sanofi as head of the diabetes and cardio operation, headed back to Bayer as the new chief of its pharma group, where he began his career. Sanofi, meanwhile, recruited Bayer’s Dieter Weinand — who Oelrich is replacing — and assigned him to the office in Bridgewater, NJ, where he’ll run a new primary care unit that combines diabetes/cardio and their “Established Products” group.
Sanofi is also carving out a new group called “China and emerging markets” and assigning it to Olivier Charmeil, who will be in charge. China has grown swiftly into Sanofi’s second largest market, and they want to add an emphasis here as the Asian market continues to see its healthcare market swell rapidly.
Genzyme, Sanofi Pasteur and Consumer Healthcare remain unchanged, says Sanofi.
Image: Olivier Charmeil Sanofi
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,600+ biopharma pros who read Endpoints News by email every day.Free Subscription